Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
ADIL Price/Volume Stats
Current price | $1.54 | 52-week high | $14.00 |
Prev. close | $1.63 | 52-week low | $0.77 |
Day low | $1.50 | Volume | 95,900 |
Day high | $1.65 | Avg. volume | 4,619,373 |
50-day MA | $1.80 | Dividend yield | N/A |
200-day MA | $2.40 | Market Cap | 6.24M |
ADIL Stock Price Chart Interactive Chart >
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial Pharmaceuticals Receives Final Reimbursement Payment from AdovateCHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that on December 16, 2023, it received the final development cost reimbursement payment of $350,000 from Adovate, LLC under the terms of the final asset purchase agreement (the “FAA”) executed with Adovate |
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementCHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq today that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,00 |
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateAdvancing Discussions with Potential Strategic Partners Received Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules; Extends Cash Runway into Q4 2024 CHARLOTTESVILLE, Va., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera |
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine ConferenceCHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Chief Medical Officer of Adial, Bankole Johnson, D.Sc., M.D., and Key Opinion Leaders Jonathan Chick, M.D., Hannu Alho, M.D., and Icro Maremmani M.D., will be presenting at The Annual International |
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to BuyAdial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
ADIL Price Returns
1-mo | 32.76% |
3-mo | 26.24% |
6-mo | -22.61% |
1-year | -80.75% |
3-year | -97.16% |
5-year | -97.66% |
YTD | -17.20% |
2023 | -65.40% |
2022 | -92.04% |
2021 | 58.82% |
2020 | -29.46% |
2019 | -52.93% |
Loading social stream, please wait...